ARS Pharmaceuticals Inc [SPRY] stock prices are up 4.24% to $11.79 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SPRY shares have gain 6.22% over the last week, with a monthly amount glided 15.14%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Roth Capital started tracking the stock with Buy rating on September 04, 2025, and set its price target to $40. On March 07, 2025, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $30 on the stock. Oppenheimer started tracking the stock assigning an Outtperform rating and suggested a price target of $40 on February 10, 2025. Cantor Fitzgerald initiated its recommendation with an Overweight. Raymond James upgraded its rating to Strong Buy for this stock on August 13, 2024, and upped its price target to $22. In a note dated August 12, 2024, Leerink Partners reiterated an Outperform rating on this stock and boosted its target price from $19 to $20.
The stock price of ARS Pharmaceuticals Inc [SPRY] has been fluctuating between $6.66 and $18.90 over the past year. Currently, Wall Street analysts expect the stock to reach $31 within the next 12 months. ARS Pharmaceuticals Inc [NASDAQ: SPRY] shares were valued at $11.79 at the most recent close of the market. An investor can expect a potential return of 162.93% based on the average SPRY price forecast.
Analyzing the SPRY fundamentals
The ARS Pharmaceuticals Inc [NASDAQ:SPRY] reported sales of 142.77M for trailing twelve months, representing a surge of 1471.62%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -0.64%, Pretax Profit Margin comes in at -0.56%, and Net Profit Margin reading is -0.56%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.39 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that ARS Pharmaceuticals Inc [NASDAQ:SPRY]’s Current Ratio is 6.66. Further, the Quick Ratio stands at 6.51, while the Cash Ratio is 1.17. Considering the valuation of this stock, the price to sales ratio is 8.16, the price to book ratio is 7.89.
Transactions by insiders
Recent insider trading involved Dorsey Brian, Chief Operating Officer, that happened on Nov 13 ’25 when 21828.0 shares were sold. Chief Business Officer, Chakma Justin completed a deal on Nov 12 ’25 to sell 0.17 million shares. Meanwhile, Officer BRIAN T DORSEY bought 21828.0 shares on Nov 13 ’25.
